Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Gentronix Extends Toxicology Screening Services to Apoptosis

Published: Tuesday, August 13, 2013
Last Updated: Monday, August 12, 2013
Bookmark and Share
Company adds apoptosis testing to provide follow-up for micronucleus positive results.

Apoptosis, or programmed cell death, is used by the body to remove unwanted, damaged or senescent cells from tissues. Gentronix has announced the expansion of its service testing portfolio with the launch of Apoptosis Suite: a set of in vitro assays to detect apoptosis induction during micronucleus assessment.

New compounds being developed as pharmaceuticals, agrichemicals etc are subject to genotoxicity assessment in order to identify potential carcinogenicity.

However, positive genotoxicity results alone need not terminate the development of a compound. One reason for this is that some genotoxicity tests have recognized mechanisms for the generation of misleading, or ‘false positive’ results.

For example, the widely used micronucleus test can produce positive results as a consequence of ‘apoptosis’, which can be induced by both genotoxic and non-genotoxic mechanisms.

Thus when a compound produces a positive micronucleus test result, it is valuable to understand the context of the result in relation to cytotoxicity and apoptosis induction.

Activation of apoptotic pathways at similar doses to those inducing micronucleus formation can provide valuable weight of evidence in de-risking the positive result. This would then trigger the application of other genotoxicity test methods, such as the Ames test, GreenScreen HC or BlueScreen HC assays.

A positive Apoptosis suite result, combined with a negative Ames test or GreenScreen HC / BlueScreen HC result would suggest apoptosis may be the cause of a misleading positive result in the in vitro micronucleus test.

The Apoptosis Suite comprises of: an Annexin-V Affinity Assay, a Caspase 3/7 Assay and general cytotoxicity measures covering cellular proliferation and viability.

Phosphatidylserine (PS) is a phospholipid that is normally only present on the inner leaflet of cell membranes, but during apoptosis it is translocated to the extracellular membrane leaflet, marking the cell as a target for phagocytosis.

Fluorescently labelled recombinant Annexin-V preferentially binds to the translocated PS and is detected using flow cytometry. Caspases are proteases that play a key role in apoptosis in mammalian cells.

Adding a luminogenic Caspase 3/7 substrate results in cell lysis followed by caspase cleavage with an attendant ‘glow-type’ luminescence that is proportional to the amount of caspase activity present.

The combination of these assays, alongside general cellular toxicity measures, provides strong evidence for the presence or absence of an apoptotic mechanism.

Dr Steve Beasley, Commercial Director at Gentronix, commented: “Our Apoptosis Suite is a powerful tool to help determine the context of a positive genotoxicity result identified during early micronucleus test screening. This latest addition to our service offering highlights our commitment to expanding our range of assays and services in line with our customers’ needs. It enables toxicologists to better assess screening results and where necessary modify candidate compounds to eliminate genotoxicity, while still keeping the desired active properties.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gentronix Signs First Japanese Contracted Screening Collaboration with Kowa
Gentronix Ltd. has announced the company's first contracted screening project in Japan, with a major Japanese pharmaceutical manufacturer, Kowa Company, Ltd.
Thursday, October 04, 2012
Gentronix Expands Specialist Sales Team in US and Europe
Expansion of sales teams with the appointments of Dorothy Zelent and Simon Johns.
Friday, February 17, 2012
Gentronix Partner with BioQuanta
The agreement covers the commercialization of the Mitoxis® functional metabolomics platform from BioQuanta.
Thursday, November 10, 2011
Gentronix and Apredica Ally to Create Predictive-Toxicology Service
Joint service offering expected to increase drug development success and the safety of new drugs on the market.
Thursday, June 11, 2009
Improved In Vitro Genotoxicity Testing to Reduce Animal Testing
In conjunction with the University of Manchester, Gentronix has been granted a research award of £133,024.
Thursday, August 10, 2006
Gentronix Secures R&D Award
The two-year grant will provide Gentronix with two scientists, cell culture facilities, and supporting laboratory instrumentation at its Manchester Incubator Core Technology Facility premises.
Tuesday, April 11, 2006
Scientific News
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Potential Target for Revolutionary Antibiotics
An international team of including the Lomonosov Moscow State University researchers discovered which enzyme enables Escherichia coli bacterium (E. coli) to breathe.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!